KDA
MRNA icon

Kraft Davis & Associates’s Moderna MRNA Stock Holding History

Kraft Davis & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$218K Buy
+1,252
New +$205K 0.09% 94

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kraft Davis & Associates's MRNA Position: Q4 2022 in Review

Kraft Davis & Associates opened a new position in Moderna (MRNA) in Q4 2022: 1,252 shares worth $218K. The stake represents 0.09% of the portfolio and ranks #94 among its holdings.

1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Kraft Davis & Associates held 1,252 shares of Moderna worth $218K as of Q4 2022.
  • Moderna was a new Kraft Davis & Associates position in Q4 2022.
  • Moderna made up 0.09% of Kraft Davis & Associates's portfolio in Q4 2022, its #94 holding.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Kraft Davis & Associates's 13F filing for Q4 2022, filed 15 Feb 2023.